Ellen Kapiteijn

16.7k total citations · 2 hit papers
204 papers, 9.3k citations indexed

About

Ellen Kapiteijn is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ellen Kapiteijn has authored 204 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Oncology, 62 papers in Molecular Biology and 37 papers in Immunology. Recurrent topics in Ellen Kapiteijn's work include Cancer Immunotherapy and Biomarkers (64 papers), Cutaneous Melanoma Detection and Management (51 papers) and CAR-T cell therapy research (51 papers). Ellen Kapiteijn is often cited by papers focused on Cancer Immunotherapy and Biomarkers (64 papers), Cutaneous Melanoma Detection and Management (51 papers) and CAR-T cell therapy research (51 papers). Ellen Kapiteijn collaborates with scholars based in Netherlands, United States and France. Ellen Kapiteijn's co-authors include Cornelis J.�H. van de Velde, Irıs D. Nagtegaal, Hein Putter, Corrie A.M. Marijnen, J. Han van Krieken, J.W.H. Leer, Willem H. Steup, Theo Wiggers, Bengt Glimelius and Lars Påhlman and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Medicine.

In The Last Decade

Ellen Kapiteijn

185 papers receiving 9.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer

2001 3.1k citations Ellen Kapiteijn et al. profile →
Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control

2002 646 citations Ellen Kapiteijn et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen Kapiteijn Netherlands	37	7.6k	4.8k	1.4k	1.2k	1.0k	204	9.3k
Ari David Baron United States	25	7.6k 1.0×	2.3k 0.5×	3.4k 2.5×	974 0.8×	3.5k 3.5×	71	12.9k
Renata Ferrarotto United States	33	2.7k 0.4×	1.6k 0.3×	975 0.7×	431 0.4×	933 0.9×	210	4.7k
Jonathan E. Rosenberg United States	51	5.5k 0.7×	7.0k 1.5×	4.1k 3.0×	1.1k 0.9×	4.2k 4.2×	404	13.5k
Lee S. Rosen United States	50	8.4k 1.1×	1.8k 0.4×	3.8k 2.7×	442 0.4×	3.6k 3.6×	232	12.1k
Frederick L. Greene United States	20	3.8k 0.5×	2.5k 0.5×	2.2k 1.6×	257 0.2×	892 0.9×	43	6.8k
Jimmy J. Hwang United States	32	2.5k 0.3×	780 0.2×	814 0.6×	833 0.7×	940 0.9×	159	4.2k
Ranee Mehra United States	38	4.1k 0.5×	1.4k 0.3×	2.3k 1.7×	954 0.8×	1.5k 1.5×	194	6.5k
Gwen Fyfe United States	10	5.7k 0.8×	1.1k 0.2×	2.4k 1.7×	459 0.4×	3.0k 3.0×	13	9.0k
Donna M. Gress United States	6	2.5k 0.3×	2.1k 0.4×	2.1k 1.5×	202 0.2×	706 0.7×	12	5.5k
W. Heim United States	16	6.6k 0.9×	1.3k 0.3×	3.0k 2.2×	454 0.4×	3.3k 3.3×	23	10.1k

Countries citing papers authored by Ellen Kapiteijn

Since Specialization

Citations

This map shows the geographic impact of Ellen Kapiteijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Kapiteijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Kapiteijn more than expected).

Fields of papers citing papers by Ellen Kapiteijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Kapiteijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Kapiteijn. The network helps show where Ellen Kapiteijn may publish in the future.

Co-authorship network of co-authors of Ellen Kapiteijn

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Kapiteijn. A scholar is included among the top collaborators of Ellen Kapiteijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Kapiteijn. Ellen Kapiteijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verdegaal, Els M.E., Monique K. van der Kooij, Caroline E. van der Minne, et al.. (2025). Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα. Clinical Cancer Research. 31(13). 2628–2638. 1 indexed citations

Huibers, Anne, Andrew Wong, Mark C. Burgmans, et al.. (2025). Management of liver metastases from uveal melanoma. British journal of surgery. 112(8). 1 indexed citations

Schrader, Anne M.R., et al.. (2024). Melanoma arising from pre-existing naevus in carriers of a germline CDKN2A pathogenic variant. British Journal of Dermatology. 192(3). 546–548.

Vos, Joris L., Joleen J.H. Traets, Xiaohang Qiao, et al.. (2024). Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. JCI Insight. 9(21). 5 indexed citations

Santegoets, Saskia J., Simon P. Mooijaart, Diana van Heemst, et al.. (2024). Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy. Immunity & Ageing. 21(1). 83–83. 2 indexed citations

Aarts, Maureen J.B., Franchette van den Berkmortel, Christian U. Blank, et al.. (2024). Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.. Journal of Clinical Oncology. 42(16_suppl). 9573–9573. 1 indexed citations

Blank, Christian U., Richard A. Scolyer, Bart A. van de Wiel, et al.. (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. Journal of Clinical Oncology. 42(17_suppl). LBA2–LBA2. 9 indexed citations

Menzies, Alexander M., Robyn P.M. Saw, Winan J. van Houdt, et al.. (2024). Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.. Journal of Clinical Oncology. 42(17_suppl). LBA9584–LBA9584.

Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660. 2 indexed citations

10.

Reijers, Irene L. M., Alexander M. Menzies, Judith M. Versluis, et al.. (2023). The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.. Journal of Clinical Oncology. 41(16_suppl). 101–101. 6 indexed citations

11.

Kapiteijn, Ellen, et al.. (2023). 1153P Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients. Annals of Oncology. 34. S689–S689. 1 indexed citations

12.

Burgmans, Mark C., Frank M. Speetjens, Arian R. van Erkel, et al.. (2023). Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology. 46(3). 350–359. 16 indexed citations

13.

Kapiteijn, Ellen, et al.. (2022). Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments. Cancers. 14(21). 5426–5426. 6 indexed citations

14.

Bijlstra, Okker D., Mark C. Burgmans, Ellen Kapiteijn, et al.. (2022). The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics. 12(3). 715–715. 8 indexed citations

15.

Piperno‐Neumann, Sophie, James Larkin, Richard D. Carvajal, et al.. (2020). Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Molecular Cancer Therapeutics. 19(4). 1031–1039. 41 indexed citations

16.

Kapiteijn, Ellen, et al.. (2019). Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. Drugs & Aging. 36(10). 927–938. 70 indexed citations

17.

Piperno‐Neumann, Sophie, Josep M. Piulats, Matthias Goebeler, et al.. (2019). Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. Cancers. 11(6). 817–817. 14 indexed citations

18.

Moel, Emma C. de, Elisa A. Rozeman, Ellen Kapiteijn, et al.. (2018). Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research. 7(1). 6–11. 129 indexed citations

19.

Melief, Sara M., Valeria Visconti, Marten Visser, et al.. (2017). Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. Cancer Immunology Research. 5(2). 170–179. 24 indexed citations

20.

Kvistborg, Pia, Daisy Philips, Sander Kelderman, et al.. (2014). Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. Science Translational Medicine. 6(254). 254ra128–254ra128. 288 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact